Ipamorelin

Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the ghrelin receptor (also known as the Growth Hormone Secretagogue Receptor, or GHS-R1a). It belongs to the GHRP (Growth Hormone Releasing Peptide) family but is distinguished by one defining characteristic that has made it the preferred GHRP in clinical peptide therapy: exceptional selectivity. Where other GHRPs like GHRP-2, GHRP-6, and Hexarelin produce varying degrees of cortisol, prolactin, and ACTH elevation alongside their GH-stimulating effects, Ipamorelin stimulates GH release with minimal impact on these other hormonal pathways.

This selectivity has significant practical implications. Elevated cortisol works against the anabolic and recovery goals that most people pursue when using GH secretagogues — cortisol is catabolic, promotes fat storage (particularly visceral fat), disrupts sleep, and counteracts many of GH's benefits. Elevated prolactin can cause its own set of side effects including sexual dysfunction and water retention. Ipamorelin's near-absence of these effects means the GH stimulus it generates is essentially "clean" — the benefits of increased GH and IGF-1 without the hormonal noise.

The pharmacological basis for Ipamorelin's selectivity lies in its distinct binding profile. Studies comparing GHRPs at the receptor level show that Ipamorelin achieves its GH-releasing activity through a specific subset of GHS receptor interactions that don't cross-activate the ACTH/cortisol pathways as strongly. This has been confirmed in both in vitro receptor binding studies and in vivo animal and human trials. Multiple clinical studies confirm that Ipamorelin produces dose-dependent, robust GH increases without statistically significant cortisol or prolactin changes at therapeutic doses.

In clinical practice, Ipamorelin is almost always paired with a GHRH analog (typically CJC-1295 without DAC) to produce synergistic GH release. The combination mimics the natural two-signal system your body uses: GHRH from the hypothalamus primes the pituitary (CJC's role), and ghrelin-family signals amplify the resulting pulse (Ipamorelin's role). This CJC/Ipamorelin protocol is the most prescribed peptide combination in anti-aging and longevity medicine today, used by thousands of patients under clinical supervision at hormone optimization clinics across North America.